Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.37 |
| ▸ | CDA | P32320 | 3/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23353386 | 1.00 | TK2 (0.37) | TK2CDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14510444 | 1.00 | TK2 (0.37) | TK2CDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL25053728 | 0.89 | TK2 (0.35) | TK2CDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL24052323 | 0.84 | PRKCA (0.31) | — | |
| SCHEMBL21283173 | 0.84 | CDA (0.47) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL26798971 | 0.83 | CDA (0.39) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL19840323 | 0.82 | CHEK1 (0.32) | — | |
| SCHEMBL21277435 | 0.78 | CDA (0.40) | TK2CDALGALS8MEN1KMT2A | |
| SCHEMBL31685726 | 0.76 | MEN1 (0.35) | CDALGALS8MEN1KMT2A | |
| SCHEMBL23906506 | 0.76 | ALDH1A1 (0.41) | CDASLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | TK2 305/4885CDA 78/4885SLC28A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.